Cancer Family
Adnexal Neoplasm
CI-CAN-00000005Explore in graph →
Non-malignant777 active trials5 approved drugs94 evidence items
- NCIt
- C212119
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000005Explore in graph →
Clinical trials
3,522 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05043402 | A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer | unknown | Phase 3 | 400 | OncXerna Theraputics, Inc.INDUSTRY | 0 | Aug 15, 2022 | clinicaltrials |
| NCT03934827 | MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour(MICROBIOME) | unknown | Phase 1 | 120 | Imperial College LondonOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT05496517 | Ovarian Cancer Individualized Scoring System Scoring System(OCISS) | unknown | — | 1,000 | Assiut UniversityOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT05479487 | Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment | unknown | Phase 2 | 132 | Xiaohua Wu MDOTHER | 0 | Jul 29, 2022 | clinicaltrials |
| NCT02562365 | Adjuvant Chemotherapy of Three-step Regimen in Ovarian Cancer(ACTS) | unknown | Phase 2 | 130 | Xiaohua Wu MDOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT05440578 | First-line Olaparib Combined With Bevacizumab Maintenance Therapy | unknown | — | 50 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Jul 1, 2022 | clinicaltrials |
| NCT04864431 | Vitamin D and Pre Cachexia and Cancer Cachexia in Epithelial Ovarian Cancer(VitD) | unknown | N/A | 54 | Indonesia UniversityOTHER | 1 | Jun 22, 2022 | clinicaltrials |
| NCT05422183 | Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer | unknown | Phase 2 | 20 | Zhongda HospitalOTHER | 1 | Jun 16, 2022 | clinicaltrials |
| NCT05410015 | Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Ovarian Cancer | unknown | — | 300 | Peking Union Medical College HospitalOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT05410028 | New Serum Biomarkers for Monitoring Early Diagnosis of Ovarian Cancer Recurrence | unknown | — | 1,000 | Peking Union Medical College HospitalOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT05385068 | A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi(t) | unknown | Phase 2 | 35 | Peking Union Medical College HospitalOTHER | 0 | May 23, 2022 | clinicaltrials |
| NCT02494791 | Universal Screening for Lynch Syndrome in Women With Endometrial and Non-Serous Ovarian Cancer(LS2) | unknown | N/A | 886 | University Health Network, TorontoOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT05375526 | Magtrial: Magtrace® as Tracer for Sentinel Lymph Node Detection in Early Stage Epithelial Ovarian Cancer | unknown | N/A | 10 | Maastricht University Medical CenterOTHER | 1 | May 16, 2022 | clinicaltrials |
| NCT04235556 | Integrated Care Pathway in Oncology (PASSION)(PASSION) | unknown | — | 1,800 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 13, 2022 | clinicaltrials |
| NCT05371301 | Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer | unknown | Phase 3 | 200 | Fudan UniversityOTHER | 1 | May 12, 2022 | clinicaltrials |
| NCT02033616 | Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas | unknown | Phase 2 | 99 | Aivita Biomedical, Inc.INDUSTRY | 1 | Apr 25, 2022 | clinicaltrials |
| NCT04229615 | A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy | unknown | Phase 3 | 690 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 25, 2022 | clinicaltrials |
| NCT05342506 | Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies | unknown | Phase 2 | 30 | Peking Union Medical College HospitalOTHER | 0 | Apr 22, 2022 | clinicaltrials |
| NCT05311579 | Niraparib Plus Anlotinib for Recurrent Ovarian Cancer | unknown | Phase 2 | 36 | Lei LiOTHER | 1 | Apr 13, 2022 | clinicaltrials |
| NCT05316376 | Effect of Albumin-bound Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian, Fallopian Tube or Peritoneal Cancer: A Phase 2 Single Center Clinical Trial | unknown | Phase 2 | 78 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Apr 7, 2022 | clinicaltrials |
| NCT05310344 | Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer | unknown | Phase 2 | 50 | Lei LiOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05310357 | Chromosomal Instability in Ovarian Cancer | unknown | — | 300 | Lei LiOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05310370 | HRD and Resistance to PAPPi in EOC Patients | unknown | — | 400 | Lei LiOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05274867 | Development of a Patient Reported Outcome Measure for Advanced Ovarian Cancer Patients Receiving Surgical and Chemotherapy Treatment(PROM-OSP) | unknown | — | 137 | The Christie NHS Foundation TrustOTHER | 0 | Mar 11, 2022 | clinicaltrials |
| NCT05273944 | Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese Patients | unknown | Phase 1 | 80 | Shenzhen Kangzhe Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 10, 2022 | clinicaltrials |
| NCT05270720 | Dendritic Cell Vaccination With Standard Postoperative Chemotherapy for the Treatment of Adult Ovarian Cancer | unknown | Phase 1 | 9 | West China Second University HospitalOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT03542669 | Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer | unknown | Phase 1 | 9 | Peking University People's HospitalOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT05255861 | An Exploratory Study of HRD Score in Chinese Ovarian Cancer Patients Benefiting From PARP Inhibitor Targeted Therapy | unknown | — | 300 | Xin WuOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT05244811 | Treat of Functional Ovarian Cysts by Compare Between Cocs and Progesterone Only Pills | unknown | Phase 3 | 60 | Sohag UniversityOTHER | 0 | Feb 17, 2022 | clinicaltrials |
| NCT05180851 | Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study(YSCH-01) | unknown | Early Phase 1 | 28 | Shanghai Fengxian District Central HospitalOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT05211557 | Study of Fully Human B7H3 CAR-T in Treating Recurrent Malignant Ovarian Cancer | unknown | Phase 1 / Phase 2 | 15 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT05187208 | PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer(POLO) | unknown | Phase 4 | 102 | Seoul National University HospitalOTHER | 0 | Jan 26, 2022 | clinicaltrials |
| NCT01042522 | Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors | unknown | Phase 2 | 63 | GOG FoundationNETWORK | 1 | Jan 25, 2022 | clinicaltrials |
| NCT05174377 | CADx - Radiomics to Distinguish the Origin of Ovarian Tumors(CADx) | unknown | — | 600 | Gynaecologisch Oncologisch Centrum ZuidOTHER | 1 | Jan 25, 2022 | clinicaltrials |
| NCT05175326 | Study on the Consistency Evaluation of Organoids Used in the Clinical Treatment of Ovarian Cancer With Anti-tumor Drugs | unknown | — | 64 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT05170594 | A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer | unknown | Phase 2 | 60 | The Second Affiliated Hospital of Shandong First Medical UniversityOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT04375956 | Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients(MITO 27) | unknown | Phase 2 | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Dec 20, 2021 | clinicaltrials |
| NCT05153603 | Outcomes of First-line Olaparib Mono-maintenance therapy-a Multicenter, Retrospective Study Using Data From Real-world Clinical Setting | unknown | — | 50 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Dec 10, 2021 | clinicaltrials |
| NCT05145218 | A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer | unknown | Phase 3 | 405 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 8, 2021 | clinicaltrials |
| NCT05146505 | miRNAs in High Grade Serous Ovarian Cancer(MIROC) | unknown | — | 150 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Dec 6, 2021 | clinicaltrials |
| NCT04620954 | Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin(ORION-02) | unknown | Phase 1 / Phase 2 | 31 | National Cancer Centre, SingaporeOTHER | 1 | Dec 1, 2021 | clinicaltrials |
| NCT03979339 | Feasibility of a New Technology for Isolating Circulating Tumour Cells(CTC-SMMiL-E) | unknown | N/A | 76 | Centre Oscar LambretOTHER | 1 | Oct 13, 2021 | clinicaltrials |
| NCT05072327 | Mohs Surgery Combind With Cryotherapy for Eyelid Malignant Tumors. | unknown | N/A | 120 | Sun Yat-sen UniversityOTHER | 1 | Oct 8, 2021 | clinicaltrials |
| NCT04214782 | Detection of Ovarian Cancer Using an Artificial Intelligence Enabled Transvaginal Ultrasound Imaging Algorithm | unknown | N/A | 10,000 | Tongji HospitalOTHER | 0 | Oct 7, 2021 | clinicaltrials |
| NCT04214964 | Clinical Characters of the Diagnosis and Treatment of Gynecological Malignant Tumors in China : A Real World Study | unknown | — | 10,000 | Tongji HospitalOTHER | 1 | Oct 7, 2021 | clinicaltrials |
| NCT05069818 | Variance of HRD From Paired Ovarian Cancer(HOPEII) | unknown | — | 50 | Xiaoxiang ChenOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT00108745 | Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer | unknown | Phase 3 | 1,157 | GOG FoundationNETWORK | 1 | Sep 30, 2021 | clinicaltrials |
| NCT00954174 | Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer | unknown | Phase 3 | 637 | GOG FoundationNETWORK | 2 | Sep 30, 2021 | clinicaltrials |
| NCT01366183 | Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer | unknown | — | 290 | Gynecologic Oncology GroupNETWORK | 1 | Sep 30, 2021 | clinicaltrials |
| NCT05059782 | Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer | unknown | N/A | 150 | Xi'an Jiaotong UniversityOTHER | 1 | Sep 28, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Aug 15, 2022source: clinicaltrials